New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ABBV;ABT;ALJ;ALDW;FB;WGP;WES;LRCX;WHF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 24, 2015
09:37 EDTFBActive equity options trading on open
Subscribe for More Information
07:23 EDTABBVAbbVie price target raised to $81 from $76 at UBS
Subscribe for More Information
06:16 EDTFBEU considers new regulator to oversee internet companies, WSJ reports
Subscribe for More Information
06:11 EDTLRCXKLA-Tencor downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
05:58 EDTFBFacebook implied volatility of 24 at lower end of index mean range
05:32 EDTABBVAbbVie announces priority review from FDA for OBV/PTV/r
AbbVie has announced that the FDA has accepted its New Drug Application, or NDA, and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir, or OBV/PTV/r, with ribavirin, or RBV. The NDA is for the treatment of adults with chronic genotype 4, or GT4, hepatitis C virus, or HCV, infection. AbbVie's regimen is the first all-oral, interferon-free therapy being evaluated by the FDA for patients in the United States with chronic GT4 HCV infection. This submission affirms the company's commitment to seeking access to curative therapy for patients living with chronic HCV infection. The FDA granted priority review to AbbVie for the regimen based in part on data from the PEARL-I study, which was recently published online in The Lancet. The FDA grants priority review designation to investigational therapies that treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. This designation shortens the regulatory review period for non-new chemical entity NDAs from the normal 10 months to six months. AbbVie's regimen was also granted a Breakthrough Therapy designation by the FDA on June 30, 2014, a status given to investigational treatments for serious or life-threatening conditions with preliminary clinical evidence that may demonstrate substantial improvement on at least one clinically significant endpoint compared to available therapy.
April 23, 2015
14:29 EDTFBFacebook launches video ad partnership featuring Vice, The Onion, Funny or Die
Subscribe for More Information
10:55 EDTFBPac Crest an outlier with bearish note on Facebook following Q1 report
After Facebook last night reported higher than expected first quarter profits but lower than expected revenue. several analysts reacted positively to the company's results, raising their price targets on the social network operator's stock. However, Pacific Crest went against the mostly bullish trend by recommending that investors avoid the stock. WHAT'S NEW: Facebook last night reported first quarter earnings per share of 42c, versus the consensus outlook of 40c. The social network operator's revenue came in below expectations, and the company said that foreign exchange trends negatively impacted its first quarter results. Facebook forecast that foreign exchange headwinds would increase this quarter. Facebook reported that it had 936M daily active users on average last month, an increase of 17% versus the same period a year earlier. Its monthly active users climbed 13% year-over-year to 1.44B in Q1. BULLISH TAKE: Adjusting for currency, Facebook's Q1 revenue would have been 3% higher than the Street's consensus outlook, Piper Jaffray analyst Gene Munster stated. The online network's "story is firmly intact" as its results are likely to be boosted by the ramping of Instagram in 2016, WhatsApp in 2017 and Oculus in 2018, the analyst stated. He kept a $92 price target and Buy rating on the shares. Also upbeat was Deutsche Bank analyst Ross Sandler, who raised his price target on the stock to $100 from $90, saying that its currency headwinds "masked" strong Q1 results. The stock will "grind higher" on new revenue streams and product announcements, predicted Sandler, who kept a Buy rating on the shares. JPMorgan analyst Doug Anmuth raised his price target on the stock to $100 from $85, saying that the company reported strong Q1 results and that it is the best positioned Internet company over the next five years. Moreover, its video ads appear to be hitting a positive turning point, added Anmuth, who kept an Overweight rating on the name. BEARISH TAKE: Facebook's price per ad appears to have declined sequentially last quarter for the first time since early 2013, wrote Pacific Crest analyst Evan Wilson. If that trend continues, its price per ad growth will decelerate significantly this year, according to the analyst. Additionally, the company's margins are contracting and its new products are unlikely to make much of an impact this year, according to Wilson, who recommended that investors choose other stocks over Facebook. PRICE ACTION: In mid-morning trading, Facebook slid 0.7% to $84 per share.
10:02 EDTABBVAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information
09:38 EDTABBVAbbVie says cutting Humira spending 'not a prudent strategy'
Subscribe for More Information
09:35 EDTFBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL FB PBR TWTR AA COST TSLA AMZN TXN BAC
09:29 EDTABBVAbbVie sees Q2 EPS $1.04-$1.06, consensus $1.05
Subscribe for More Information
09:26 EDTABBVAbbVie says not completly immune to forex, but hedges protect bottom line impact
Subscribe for More Information
09:16 EDTABBVAbbVie says intends to enforce IP if Humira challenged by biosimilar applicant
Subscribe for More Information
09:07 EDTABBVAbbVie says remains on track to complete Pharmacyclics acquisition in Q2
09:04 EDTABBVAbbVie says continues to see strong underlying demand for Humira
Comment from earnings conference call.
08:27 EDTFBFacebook growth slowing, margins contracting, says Pacific Crest
Subscribe for More Information
08:23 EDTFBFacebook reported solid results, says Brean Capital
Subscribe for More Information
08:19 EDTABBVEnanta announces FDA grants priority review for AbbVie treatment regimen
Subscribe for More Information
08:11 EDTFBFacebook price target raised to $94 from $84 at FBR Capital
Subscribe for More Information
07:52 EDTABBVAbbVie expects Pharmacyclics transaction to close in Q2
Subscribe for More Information
07:51 EDTABBVAbbVie raises FY15 adjusted EPS to $4.10-$4.30 from $4.05-$4.25, consensus $4.19
Subscribe for More Information
07:51 EDTABBVAbbVie reports Q1 HUMIRA sales up 26% to $3.11B
Subscribe for More Information
07:49 EDTABBVAbbVie reports Q1 adjusted EPS 94c, consensus 85c
Reports Q1 revenue $5.04B, consensus $4.98B
07:45 EDTFBFacebook price target raised to $100 from $85 at JPMorgan
JPMorgan raised its price target for Facebook shares to $100 saying the company posted strong Q1 results despite a challenging currency environment. The firm highlights Facebook's growth in organic and promoted video views as well as its better ad targeting and measurement tools. JPMorgan continues to view Facebook as the best positioned company in the internet space over the next five years. It keeps an Overweight rating on the stock.
07:28 EDTFBFacebook price target raised to $105 from $88 at RBC Capital
Subscribe for More Information
07:22 EDTFBFacebook thesis strengthened, says Credit Suisse
Credit Suisse said Facebook remains a top pick for 2015 and that its in-line quarter strengthened the firm's Outperform thesis. The firm said the quarter reaffirmed its conviction that Facebook will be able to drive revenue growth without a material increase in ad loads, consensus estimates underestimate long-term monetization potential of new products, and upward bias to estimates from Offers/Local, Instagram, WhatsApp, Oculus, and others. Credit Suisse's price target on Facebook remains $106.
07:17 EDTFBFacebook price target raised to $100 from $90 at Deutsche Bank
Subscribe for More Information
06:48 EDTFBFacebook reported strong Q1 results, says Cantor
Subscribe for More Information
05:49 EDTFBFacebook Q1 sales a 3% beat ex-currency, says Piper Jaffray
Subscribe for More Information
April 22, 2015
19:14 EDTFBOn The Fly: After Hours Movers
UP AFTER EARNINGS: Select Comfort (SCSS), up 3.3%... Alliance Fiber Optic (AFOP), up 6.9%... eBay (EBAY), up 6.2%... Cheesecake Factory (CAKE), up 5.6%... O'Reilly Automotive (ORLY), up 3.8%... Corelogic (CLGX), up 3.2%... Skechers (SKX), up 2.5%... AT&T (T), up 1.3%. ALSO HIGHER: ARRIS Group (ARRS), up 24.9% after acquiring Pace plc. for $2.1B in cash and stock... Esperion Therapeutics (ESPR), up 2.5% after being initiated with an Outperform at RBC Capital... Uniqure (QURE), up 3.7% after being initiated with an Outperform at BMO Capital. DOWN AFTER EARNINGS: Texas Instruments (TXN), down 6.7%... Las Vegas Sands (LVS), down 4.2%... Oceaneering International (OII), down 3.7%... F5 Networks (FFIV), down 2.8%... Xilinx (XLNX), down 3.3%... Qualcomm (QCOM), down 3%... Facebook (FB), down 2.2%... Tractor Supply (TSCO), down 3.1%. ALSO LOWER: Noble Corp (NE), down 1.2% after being downgraded to Underweight from Equal Weight at Morgan Stanley.
17:32 EDTFBFacebook sees total payments and other fees revenue to decline
Facebook sees total payments and other fees revenue to decline on a year-over year basis for the remainder of the year. Sees FY15 CapEx $2.7B-$$3.2B.
17:23 EDTFBNokia approaches Apple, Amazon, Facebook in sale of maps unit, Bloomberg says
Subscribe for More Information
17:22 EDTFBFacebook says FX headwinds in Q2 will be greater than Q1
17:20 EDTFBFacebook says Q1 Non-Gaap expense increased 57%
Subscribe for More Information
17:18 EDTFBFacebook says FX headwinds impacted Q1 revenue
17:14 EDTFBFacebook sees videos attracting marketers to mobile
Subscribe for More Information
17:11 EDTFBFacebook says Instagram has more than 200M daily users
Subscribe for More Information
16:03 EDTFBFacebook down $1.20 to $83.43 after Q1 results
Subscribe for More Information
16:02 EDTFBFacebook reports Q1 daily active users up 17%
Subscribe for More Information
16:01 EDTFBFacebook reports Q1 EPS 42c, consensus 40c
Subscribe for More Information
16:00 EDTFBOptions Update; April 22, 2015
iPath S&P 500 VIX Short-Term Futures down 22c to 21.30. Option volume leaders: AAPL TSLA TWTR MCD FB PBR AMZN KMI MYL C according to Track Data.
15:50 EDTABBVNotable companies reporting before tomorrow's open
Subscribe for More Information
15:30 EDTFBNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include eBay (EBAY), consensus 70c... Facebook (FB), consensus 40c... Texas Instruments (TXN), consensus 62c... Las Vegas Sands (LVS), consensus 72c... Qualcomm (QCOM), consensus $1.33... AT&T (T), consensus 62c... F5 Networks (FFIV), consensus $1.50... Plexus (PLXS), consensus 69c... Skechers (SKX), consensus $1.01... Select Comfort (SCSS), consensus 41c... Tractor Supply (TSCO), consensus 41c... Covanta (CVA), consensus (8c)... Crown Castle (CCI), consensus $1.09... Torchmark (TMK), consensus $1.05... Ameriprise (AMP), consensus $2.33... Polycom (PLCM), consensus 21c... Citrix (CTXS), consensus 65c... Core Laboratories (CLB), consensus 85c... Graco (GGG), consensus 78c... Cheesecake Factory (CAKE), consensus 48c... Equifax (EFX), consensus $1.02... SLM (SLM), consensus 7c... Xilinx (XLNX), consensus 50c... O'Reilly Automotive (ORLY), consensus $1.94... Susquehanna (SUSQ), consensus 18c... Raymond James (RJF), consensus 83c... SL Green Realty (SLG), consensus $1.49... CoreLogic (CLGX), consensus 31c... Oceaneering (OII), consensus 62c... Valmont (VMI), consensus $1.49... Brandywine Realty (BDN), consensus 32c... Weatherford (WFT), consensus 1c.
14:08 EDTABBVEarnings Watch: AbbVie's Humira sales will be focus for Q1
Subscribe for More Information
13:51 EDTFBEarnings Watch: Analysts expect Facebook to beat Q1 expectations
Subscribe for More Information
13:28 EDTFBFacebook April weekly 84 straddle priced for 5.4% movement into Q1
13:01 EDTFBFacebook technical comments ahead of results
Subscribe for More Information
09:26 EDTABTAbbott sees flat growth in Molecular Diagnostics business in Q2
Sees mid-single digit growth for Global Diagnostics growth in Q2. Sees low single digit growth for Global Vascular in Q2. Expects similar double digit growth in EPD in Q2.
09:21 EDTABTAbbott sees FY15 revenue growth to be in low single digits, consensus $20.71B
Subscribe for More Information
09:20 EDTABTAbbott sees Q2 EPS 49c-51c, consensus 52c
Subscribe for More Information
08:55 EDTABBVDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:48 EDTABTAbbott reports Q1 Nutrition sales up 6.3% to $1.67B
Subscribe for More Information
07:46 EDTABTAbbott backs FY15 adjusted EPS $2.10-$2.20, consensus $2.14
Subscribe for More Information
07:45 EDTABTAbbott reports Q1 adjusted EPS 47c, consensus 42c
Subscribe for More Information
07:10 EDTFBFacebook volatility increases into Q1 and outlook
Subscribe for More Information
07:07 EDTABBVEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
06:06 EDTFBGoogle, Facebook seek to reach billions of people without Web access, WSJ says
Subscribe for More Information
April 21, 2015
16:26 EDTLRCXOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
16:00 EDTFBOptions Update; April 21, 2015
iPath S&P 500 VIX Short-Term Futures down 1c to 21.53 Option volume leaders: AAPL TSLA TWTR GILD FB PBR AMZN C KMI KO VZ MCD according to Track Data.
15:28 EDTABTNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 42c... Boeing (BA), consensus $1.81... McDonald's (MCD), consensus $1.06... EMC (EMC), consensus 36c... Abbott Laboratories (ABT), consensus 42c... Thermo Fisher Scientific (TMO), consensus $1.61... Bank of New York Mellon (BK), consensus 59c... TE Connectivity (TEL), consensus $1.01... T. Rowe Price Group (TROW), consensus $1.14... St. Jude Medical (STJ), consensus 91c... Amphenol (APH), consensus 56c... Nielsen (NLSN), consensus 47c... Citizens Financial Group (CFG), consensus 34c... Autoliv (ALV), consensus $1.31... D.R. Horton (DHI), consensus 38c... Westinghouse Air Brake Technologies (WAB), consensus 95c... Huntington Bancshares (HBAN), consensus 19c... SEI Investments (SEIC), consensus 49c... AutoNation (AN), consensus 89c... Gentex (GNTX), consensus 25c... Ryder System (R), consensus $1.00... Owens Corning (OC), consensus 13c... NuStar Energy (NS), consensus 58c... Six Flags (SIX), consensus (67c)... Tupperware Brands (TUP), consensus 98c... MarketAxess Holdings (MKTX), consensus 64c... Lithia Motors (LAD), consensus $1.22... Knight Transportation (KNX), consensus 31c... Evercore Partners (EVR), consensus 58c... Potlatch (PCH), consensus 19c... Natus Medical (BABY), consensus 29c... AZZ (AZZ), consensus 59c... United Community Banks (UCBI), consensus 29c... Sonus Networks (SONS), consensus (31c)... Angie's List (ANGI), consensus 0c... Pacific Premier Bancorp (PPBI), consensus 27c.
12:33 EDTLRCXOn The Fly: Top stock stories at midday
Subscribe for More Information
10:55 EDTLRCXStreet Check: Lam Research defenders rewarded with post-earnings jump
Subscribe for More Information
10:01 EDTFBOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Agios Pharmaceuticals (AGIO) initiated with a Perform at Oppenheimer... Bed Bath & Beyond (BBBY) initiated with a Buy at Cantor... BioCryst (BCRX) initiated with an Outperform at FBR... Bovie Medical (BVX) initiated with an Outperform at JMP Securities... Calavo Growers (CVGW) initiated with a Buy at Janney Capital... Clorox (CLX) initiated with a Sector Weight at KeyBanc... Coach (COH) initiated with a Sell, $32 target at Cantor... Compugen (CGEN) initiated with an Outperform at Oppenheimer... Corcept Therapeutics (CORT) initiated with an Outperform at FBR Capital... Criteo (CRTO) initiated with an Outperform at Raymond James... CytRx (CYTR) initiated with an Outperform at FBR Capital... Dollar Tree (DLTR) initiated with a Buy at Cantor... Facebook (FB) initiated with a Buy at Cleveland Research... Gap (GPS) initiated with a Hold at Cantor... Genocea (GNCA) initiated with an Outperform at FBR Capital... Geron (GERN) initiated with an Outperform at Oppenheimer... Home Depot (HD) initiated with a Hold at Cantor... HubSpot (HUBS) initiated with a Buy at Needham... Jernigan Capital (JCAP) initiated with a Buy at Wunderlich... La Jolla (LJPC) initiated with an Outperform, $43 target at Oppenheimer... Lowe's (LOW) initiated with a Hold at Cantor... Lumber Liquidators (LL) initiated with a Buy, $45 target at Cantor... New Residential (NRZ) reinstated with an Outperform at Credit Suisse... Rent-A-Center (RCII) initiated with a Buy at Cantor... Ross Stores (ROST) initiated with a Hold at Cantor... Rubicon Project (RUBI) initiated with an Outperform at Raymond James... SolarCity (SCTY) initiated with an Outperform at Northland... SolarEdge (SEDG) initiated with a Buy at Canaccord... Spectrum Brands (SPB) initiated with an Overweight at KeyBanc... Summit Materials (SUM) initiated with a Buy at BB&T... Synergy Resources (SYRG) initiated with a Buy at KLR Group... Synta Pharmaceuticals (SNTA) initiated with an Outperform at FBR Capital... TJX (TJX) initiated with a Hold at Cantor... Tiffany (TIF) initiated with a Hold at Cantor... TubeMogul (TUBE) initiated with a Market Perform at Raymond James... Urban Outfitters (URBN) initiated with a Buy at Cantor... WhiteWave Foods (WWAV) initiated with a Neutral at Janney Capital... Williams-Sonoma (WSM) initiated with a Hold at Cantor... Zafgen (ZFGN) initiated with an Outperform at FBR Capital.
09:37 EDTFBActive equity options trading on open
Subscribe for More Information
09:22 EDTLRCXOn The Fly: Pre-market Movers
Subscribe for More Information
09:17 EDTFBFacebook initiated with a Buy at Cleveland Research
Subscribe for More Information
09:10 EDTLRCXLam Research price target raised to $75 from $68 at Susquehanna
Subscribe for More Information
07:52 EDTLRCXLam Research price target raised to $100 on strong results at BofA/Merrill
Subscribe for More Information
07:41 EDTLRCXLam Research price target raised to $95 from $88 at JPMorgan
Subscribe for More Information
07:11 EDTLRCXMicron does not have negative read through from Lam results, says RBC Capital
RBC Capital says that Lam Research's (LRCX) beat and raise results do not increase its concern about oversupply in the memory market. RBC believes that the results indicate a market share shift, not an increase in aggregate DRAM spending. RBC says that DRAM prices are stable, and it keeps an Outperform rating on Micron (MU).
April 20, 2015
19:21 EDTLRCXSemiconductor equipment stocks rising after Lam Research Q3 results
Subscribe for More Information
18:48 EDTLRCXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Lam Research (LRCX), up 9.2%... Fortinet (FTNT), up 9%. ALSO HIGHER: Lumber Liquidators (LL), up 2% after being initiated with a Buy, $45 target at Cantor... Geron (GERN), up 2.2% after being initiated with an Outperform at Oppenheimer... Applied Materials (AMAT), up 1.6% after Lam Research reported quarterly results. DOWN AFTER EARNINGS: Sanmina (SANM), down 10.5%... IBM (IBM), down marginally... Rambus (RMBS), down 3.7%.
16:12 EDTLRCXLam Research sees Q4 EPS $1.46, plus or minus 7c, consensus $1.35
Subscribe for More Information
16:11 EDTLRCXLam Research reports Q3 EPS $1.40, consensus $1.30
Subscribe for More Information
16:01 EDTFBOptions Update; April 20, 2015
iPath S&P 500 VIX Short-Term Futures down 78c to 21.52. Option volume leaders: AAPL VZ PBR TWTR TSLA TWTR NFLX MCP FB AMZN AA C according to Track Data.
15:37 EDTLRCXNotable companies reporting after market close
Subscribe for More Information
14:32 EDTABBVPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
13:58 EDTLRCXLam Research technical comments ahead of earnings
Subscribe for More Information
10:38 EDTFBFacebook volatility elevated into Q1 and outlook
Facebook April weekly call option implied volatility is at 73, May is at 39, June 30, September is at 29; compared to its 26-week average of 30 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 22.
09:36 EDTFBActive equity options trading on open
Subscribe for More Information
07:56 EDTFBFacebook Q1 results should beat expectations, says Oppenheimer
Subscribe for More Information
07:20 EDTABBVAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:18 EDTABBVAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
07:04 EDTFBFacebook Q1 results should beat expectations, says Cantor
Subscribe for More Information
06:19 EDTALDWCiti still bullish on U.S. Refiners, Marathon Petroleum a top pick
Subscribe for More Information
05:51 EDTFBEU calls for 'level playing field' in telecoms market, Financial Times reports
Subscribe for More Information
April 19, 2015
12:41 EDTLRCXKroger, Dollar General, others can be bought and held for 3 years, Barron's says
Shares of PACCAR (PCAR), Lam Research (LRCX), Kroger (KR), Autoliv (ALV), Archer Daniels (ADM), and Dollar General (DG) should be bought and held for the next three years due to high return on invested capital, Barron's contends in a feature article. Reference Link
April 17, 2015
16:50 EDTABBVAbbVie extends exchange offer to acquire Pharmacyclics
Subscribe for More Information
April 16, 2015
15:39 EDTFBFacebook volatility elevated into Q1 and outlook
Subscribe for More Information
11:46 EDTFBStocks with call strike movement; FB BABA
Subscribe for More Information
11:07 EDTLRCXTSMC capex cut not worrisome for semi equipment makers, says Summit Research
Subscribe for More Information
05:58 EDTFBIndian media groups back out of Facebook's Internet.org, Financial Times reports
Subscribe for More Information
April 15, 2015
19:08 EDTABBVEnanta confirms AbbVie hepatitis C treatment granted priority review in Japan
Subscribe for More Information
19:03 EDTABBVAbbVie's chronic hepatitis C treatment granted priority review in Japan
Subscribe for More Information
08:27 EDTALJDelek, Alon USA deal should create additional value, says Cowen
Subscribe for More Information
07:41 EDTABTEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
06:41 EDTLRCXCiti recommends Applied Materials, Lam after Intel capex cut
Subscribe for More Information
06:18 EDTFBApple, Google, others doubling down on European operations, WSJ reports
Subscribe for More Information
April 14, 2015
18:30 EDTALJOn The Fly: After Hours Movers
Subscribe for More Information
17:16 EDTALJDelek US to acquire 48% ownership interest in Alon USA Energy
Delek US Holdings (DK) announced that it has entered into a definitive stock purchase agreement with Alon Israel Oil Company to acquire approximately 33.7M shares, or approximately 48% of the outstanding shares, of Alon USA Energy (ALJ) common stock owned by Alon Israel. Prior to commencing negotiations with Alon Israel, Delek US entered into a stockholder agreement with Alon USA. During the first year following the closing of this transaction, the agreement allows Delek US to acquire up to 49.99 percent of the outstanding shares of Alon USA at its discretion, with additional ownership above this threshold subject to approval of Alon USA’s board of directors. The stockholder agreement will expire on the first anniversary of the closing of this transaction, and Delek US will then have no further restrictions on ownership in Alon USA. The consideration to be paid by Delek US to acquire the Alon USA common stock will consist of the issuance of 6M shares of restricted Delek US common stock to Alon Israel, an unsecured $145M promissory note payable to Alon Israel maturing in January 2021 and $200M of cash that will be funded with a combination of cash on hand and borrowings on new or existing credit facilities. An additional 200,000 shares of Delek US common stock may be issued to Alon Israel under certain circumstances as outlined in the agreement. The approximate value of the transaction consideration is $572.4M based upon a closing price of $37.90 per share of Delek US common stock on April 14. The transaction is expected to close in the second half of May subject to customary governmental and other third party approvals.
17:04 EDTLRCXSemiconductor equipment stocks lower after Intel cuts FY15 CapEx view
Subscribe for More Information
11:16 EDTFBCredit Suisse's top Internet picks
Credit Suisse's top large-cap Internet picks remain Amazon.com (AMZN) for operating margin expansion and normalizing International growth, Facebook (FB) for underestimated long-term monitization potential from growing new products, and Google (GOOGL) for a slowdown in capex and narrowing of the mobile-desktop monetization gap. The firm's top small-cap picks are LinkedIn (LNKD) for the ramp of Sales Navigator and acceleration of Marketing Solutions and Yelp (YELP) because of reduced churn and increasing mobile traffic growth and ARPU.
10:58 EDTFBStocks with call strike movement; FB BABA
Subscribe for More Information
09:06 EDTABTAbbott and Sekisui announce collaboration for coagulation testing
Abbott and Sekisui announce an agreement to offer coagulation testing solutions for laboratories worldwide. Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots. Under the agreement, Abbott will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in the United States, Europe and other regions that recognize CE Mark.
09:00 EDTFBFacebook price target raised to $80 from $72 at BMO Capital
Subscribe for More Information
07:28 EDTFBFacebook remains a top 2015 pick at JPMorgan
Subscribe for More Information
06:58 EDTLRCXLam Research should be bought on weakness, says Pacific Crest
Subscribe for More Information
April 13, 2015
16:01 EDTFBOptions Update; April 13, 2015
Subscribe for More Information
14:07 EDTABBVEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
10:00 EDTABBVOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:34 EDTABBVAbbVie upgraded on Imbruvica outlook at BMO Capital
Subscribe for More Information
07:13 EDTWESWells Fargo to hold a conference
Subscribe for More Information
07:02 EDTABBVAbbVie upgraded to Outperform from Market Perform at BMO Capital
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use